We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Celgene Corporation
Celgene Reports Record Fourth Quarter and Full Year 2008 Product Sales and Operating Profits
February 10th, 2009
Celgene Corporation (NASDAQ: CELG): REVLIMID® #1 Therapy in Multiple Myeloma Worldwide European Launch of VIDAZA® Commencing REVLIMID U.S. Duration of Therapy Increased Greater Than 25 Percent Year-Over-Year to More Than 10 Months Global Expansion from Nearly 30 to More Than 65 Countries 2008 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased More Than 50 Percent to $623 Million; GAAP Total Revenue $628 Million REVLIMID Net Product Sales Increased 49 Percent to $369 Million Global THALOMID® / Thalidomide Net Product Sales $127 Million VIDAZA Net Product Sales Increased to $70 Million Non-GAAP Operating Income Increased Over 45 Percent to $228 Million; GAAP...
